CTOs on the Move

Oratech

www.oratech.com

 
Oratech is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oratech.com
  • 475 W 10200 S
    South Jordan, UT USA 84095
  • Phone: 801.619.0282

Executives

Name Title Contact Details

Similar Companies

Aeon Biopharma

Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.

DK Sinopharma

DK Sinopharma is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Independent Pharmacy Cooperative

Independent Pharmacy Cooperative is a Sun Prairie, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignite Mental Health

Join us in the fight to end the mental health crisis plaguing our campuses and transform the future of mental health.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.